Dashboard
Manage Tickers

ARVNARVINAS, INC.

Nasdaq arvinas.com


$ 32.34 $ 0.18 (0.56 %)    

Monday, 29-Apr-2024 12:28:33 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 432.64 $ -0.51 (-0.12 %)
DIA $ 383.29 $ 0.10 (0.03 %)
SPY $ 510.04 $ -0.22 (-0.04 %)
TLT $ 88.82 $ 0.16 (0.18 %)
GLD $ 217.14 $ 1.09 (0.5 %)
$ 32.37
$ 32.16
$ 32.28 x 100
$ 0.00 x 0
$ 31.72 - $ 32.42
$ 13.57 - $ 53.08
778,717
na
1.8B
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-27-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-05-2023 03-31-2023 10-Q
5 02-23-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-03-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 03-01-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 04-28-2020 03-31-2020 10-Q
17 03-16-2020 12-31-2019 10-K
18 11-04-2019 09-30-2019 10-Q
19 08-05-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-26-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-arvinas-lowers-price-target-to-87
HC Wainwright & Co. Maintains Buy on Arvin...
04/15/2024 11:28:13

HC Wainwright & Co. analyst Andrew Fein maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $90 ...

hc-wainwright--co-maintains-buy-on-arvinas-lowers-price-target-to-87
HC Wainwright & Co. Maintains Buy on Arvin...
04/12/2024 11:15:45

HC Wainwright & Co. analyst Andrew Fein maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $90 ...

Core News & Articles
Arvinas Enters Exclusive Strategic License...
04/11/2024 11:22:03

The deal is for the worldwide development and commercialization of ARV-766, Arvinas' second generation PROTAC androgen rece...

truist-securities-reiterates-buy-on-arvinas-maintains-65-price-target
Truist Securities Reiterates Buy on Arvina...
03/25/2024 16:05:56

Truist Securities analyst Joon Lee reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $65 price target.

why-zscaler-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Zscaler Shares Are Trading Lower By 10...
03/01/2024 18:19:25

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

cooper-companies-reports-upbeat-results-joins-dell-netapp-tidewater-and-other-big-stocks-moving-higher-on-friday
Cooper Companies Reports Upbeat Results, J...
03/01/2024 16:18:21

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

barclays-maintains-overweight-on-arvinas-raises-price-target-to-60
Barclays Maintains Overweight on Arvinas, ...
02/29/2024 14:04:02

Barclays analyst Peter Lawson maintains Arvinas (NASDAQ:ARVN) with a Overweight and raises the price target from $26 to $60.

hc-wainwright--co-reiterates-buy-on-arvinas-maintains-90-price-target
HC Wainwright & Co. Reiterates Buy on Arvi...
02/28/2024 17:25:09

HC Wainwright & Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $90 price target.

bmo-capital-maintains-outperform-on-arvinas-raises-price-target-to-90
BMO Capital Maintains Outperform on Arvina...
02/28/2024 14:05:35

BMO Capital analyst Etzer Darout maintains Arvinas (NASDAQ:ARVN) with a Outperform and raises the price target from $89 to $90.

navigating-7-analyst-ratings-for-arvinas
Navigating 7 Analyst Ratings For Arvinas
02/28/2024 13:01:12

wedbush-maintains-outperform-on-arvinas-raises-price-target-to-59
Wedbush Maintains Outperform on Arvinas, R...
02/28/2024 12:54:23

Wedbush analyst Robert Driscoll maintains Arvinas (NASDAQ:ARVN) with a Outperform and raises the price target from $33 to $59.

oppenheimer-reiterates-outperform-on-arvinas-lowers-price-target-to-80
Oppenheimer Reiterates Outperform on Arvin...
02/28/2024 12:34:32

Oppenheimer analyst Matthew Biegler reiterates Arvinas (NASDAQ:ARVN) with a Outperform and lowers the price target from $95 ...

arvinas-q4-earnings-insights
Arvinas: Q4 Earnings Insights
02/27/2024 13:50:12

arvinas-q4-eps-253-misses-128-estimate-cash-balance-of-12665m-is-expected-to-provide-cash-runway-into-2027
Arvinas Q4 EPS $(2.53) Misses $(1.28) Esti...
02/27/2024 12:18:32

Arvinas (NASDAQ:ARVN) reported quarterly losses of $(2.53) per share which missed the analyst consensus estimate of $(1.28) by ...

arvinas-announces-chief-financial-officer-transition-randy-teel-phd-to-assume-the-role-of-interim-chief-financial-officer-sean-cassidy-leaving-as-of-february-29-2024
Arvinas Announces Chief Financial Officer ...
02/20/2024 21:44:08

- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Offi...

arvinas-has-dosed-the-first-subject-in-its-phase-1-trial-of-arv-102-in-development-to-treat-neurodegenerative-diseases
Arvinas Has Dosed The First Subject In Its...
02/20/2024 12:13:35

citigroup-downgrades-arvinas-to-neutral-raises-price-target-to-55
Citigroup Downgrades Arvinas to Neutral, R...
02/14/2024 13:35:45

Citigroup analyst Yigal Nochomovitz downgrades Arvinas (NASDAQ:ARVN) from Buy to Neutral and raises the price target from $3...

Core News & Articles
Carrick Therapeutics Announces First Patie...
02/14/2024 13:05:57

Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies,...

sps-commerce-posts-upbeat-results-joins-masonite-international-impinj-and-other-big-stocks-moving-higher-on-friday
SPS Commerce Posts Upbeat Results, Joins M...
02/09/2024 15:31:44

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ...

Core News & Articles
Arvinas And Pfizer's Vepdegestrant Receive...
02/06/2024 11:46:19

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION